Press Release
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology
March 3, 2017
Barcelona (Catalonia, Spain), March 7, 2017. Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced the sponsorship of the of 37th National Meeting of the Spanish Society of Pharmacology (SEF). The Meeting will be held in Barcelona from Sunday 18th to Wednesday 21th June 2017, with the British Pharmacological Society (BPS) as the main guest (http://www.sef2017.com).
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.
This meeting will display the world class research carried out not only by SEF and BPS members but also by researchers worldwide whose investigation revolves around the pharmacology field. The programme combines plenary lectures, symposia, oral presentations and posters, to stimulate the scientific discussion as well as to set new collaborations and research opportunities especially for young researchers.
Dr. José Alfón, the VP of research and developmend of Ability Pharma, will be opening the Session 14 (Pharmacology of Anti-Cancer Drugs) on Wednesday 21th June, presenting our main project ABTL0812, an autophagy-anticancer drug in Phase II clinical trials.
LATEST NEWS
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
07.10.2022
Press Release
AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022
Press Release
Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022
Press Release
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
13.06.2022
Press Release
AbilityPharma Will Attend the ESMO Gynaecological Cancers Congress 2022 in Valencia + info
10.06.2022
Press Release
AbilityPharma Will Attend BIO 2022 in San Diego as Part of the European Innovation Council (EIC) Delegation with a Booth in the European Pavilion + info